Braidwell LP Has $1.26 Million Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Braidwell LP decreased its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 90.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 801,584 shares of the biopharmaceutical company’s stock after selling 7,493,366 shares during the quarter. Braidwell LP owned 0.33% of Lexicon Pharmaceuticals worth $1,258,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of LXRX. Compagnie Lombard Odier SCmA lifted its stake in Lexicon Pharmaceuticals by 6.4% during the third quarter. Compagnie Lombard Odier SCmA now owns 100,000 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 6,000 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Lexicon Pharmaceuticals by 116.1% during the second quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 12,225 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of Lexicon Pharmaceuticals by 71.2% during the third quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 13,246 shares during the period. Victory Capital Management Inc. lifted its position in shares of Lexicon Pharmaceuticals by 44.5% in the 2nd quarter. Victory Capital Management Inc. now owns 45,341 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 13,972 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Lexicon Pharmaceuticals by 40.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 49,957 shares of the biopharmaceutical company’s stock worth $84,000 after purchasing an additional 14,411 shares during the period. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Trading Down 1.9 %

Lexicon Pharmaceuticals stock opened at $0.80 on Friday. The firm’s 50 day moving average price is $1.46 and its two-hundred day moving average price is $1.68. Lexicon Pharmaceuticals, Inc. has a twelve month low of $0.73 and a twelve month high of $3.73. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The company had revenue of $1.75 million during the quarter, compared to analyst estimates of $3.14 million. During the same period last year, the company posted ($0.21) earnings per share. On average, analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on LXRX shares. Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Friday, November 22nd. Leerink Partners set a $6.00 price target on Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research report on Friday, October 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Lexicon Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $6.00.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.